FDA grants FELIQS fast track status for FLQ-101 in ROP preventive treatment

FELIQS, a multinational clinical-stage biopharmaceutical firm headquartered in Japan, has announced that its leading asset, FLQ-101, has received Fast Track designation from the U.S. Food ... Read More